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Judith Landman-Parker, Donna Lancaster, Andrew E. Place, Karen R. Rabin, Mariana Sacchi, Rene Swanink, and
C. Michel Zwaan
A B S T R A C T
Purpose
Safe, effective treatments are needed for pediatric patients with chronicmyeloid leukemia in chronic
phase (CML-CP). Dasatinib is approved for treatment of adults and children with CML-CP. A phase I
study determined suitable dosing for children with Philadelphia chromosome–positive (Ph+)
leukemias.
Methods
CA180-226/NCT00777036 is a phase II, open-label, nonrandomized prospective trial of patients, 18
years of age receiving dasatinib. There are three cohorts: (1) imatinib-resistant/intolerant CML-CP, (2)
imatinib-resistant/intolerant CML in accelerated/blast phase or Ph+ acute lymphoblastic leukemia
(n = 17), and (3) newly diagnosed CML-CP treated with tablets or powder for oral suspension. Major
cytogenetic response . 30% for imatinib-resistant/intolerant patients and complete cytogenetic
response (CCyR) . 55% for newly diagnosed patients were of clinical interest.
Results
Of 113 patients with CML-CP, 14 (48%) who were imatinib-resistant/intolerant and 61 (73%) who
were newly diagnosed remained on treatment at time of analysis. Major cytogenetic response
. 30%was reached by 3 months in the imatinib-resistant/intolerant group and CCyR. 55%was
reached by 6months in the newly diagnosed CML-CP group. CCyR and major molecular response
by 12 months, respectively, were 76% and 41% in the imatinib-resistant/intolerant group and
92% and 52% in newly diagnosed CML-CP group. Progression-free survival by 48 months was
78% and 93% in the imatinib-resistant/intolerant and newly diagnosed CML-CP groups, re-
spectively. No dasatinib-related pleural or pericardial effusion, pulmonary edema, or pulmonary
arterial hypertension were reported. Bone growth and development events were reported in 4%
of patients.
Conclusion
In the largest prospective trial to date in children with CML-CP, we demonstrate that dasatinib is
a safe, effective treatment of pediatric CML-CP. Target responses to ﬁrst- or second-line dasatinib
were met early, and deep molecular responses were observed. Safety of dasatinib in pediatric
patients was similar to that observed in adults; however, no cases of pleural or pericardial effusion or
pulmonary arterial hypertension were reported.
J Clin Oncol 36. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Although chronic myeloid leukemia (CML) ac-
counts for , 5% of leukemias and , 1% of all
cancers in patients , 20 years of age,1 more ag-
gressive disease characteristics have been observed
in pediatric and young adult patients with CML
compared with older adults, including higher
median white blood cell counts, proportionally
larger spleen size, higher peripheral blasts counts,
and lower hemoglobin levels.2 However, there are
conﬂicting reports about the prognostic relevance
of these variables on outcomes in children.3-5
The development of safe and effective
therapies for pediatric CML is critical for the
successful treatment of this patient population.
Until recently, the BCR-ABL1–target tyrosine
kinase inhibitor (TKI) imatinib was the only TKI
approved for front-line treatment of pediatric
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patients with CML in chronic phase (CML-CP)6; however, 25% to
29%discontinue as a result of poor response or toxicity.7,8 In addition,
there were no approved therapies to treat children with imatinib-
resistant/intolerant CML-CP. There is also a need for formulations of
TKIs for younger patients who are unable to swallow tablets.9
Dasatinib is a second-generation TKI that is now approved in
tablet formulation for the treatment of pediatric patients with
CML-CP.10 Previously, dosing and safety of dasatinib in pediatric
patients were determined in phase I trials.11,12 Here, we present
results from a phase II prospective trial to further evaluate safety
and efﬁcacy of dasatinib tablet and powder for oral suspension
(PFOS) formulations in pediatric patients with CML-CP.
METHODS
Study Design
Study CA180-226 is an ongoing phase II, open-label, non-
randomized, multicenter trial investigating dasatinib in pediatric patients
with Philadelphia chromosome–positive (Ph+) leukemia (ClinicalTrials.
gov identiﬁer: NCT00777036). Patients, 18 years of age (the protocol was
amended 9 months after enrollment started to change inclusion criteria
from , 21 to , 18 years) were enrolled in three cohorts (Fig 1): (1)
patients with CML-CP resistant to or intolerant of imatinib who received
dasatinib tablets 60 mg/m2 once daily; (2) patients with accelerated- or
blastic-phase CML (CML-AP/BP) or Ph+ acute lymphoblastic leukemia
(ALL) resistant to or intolerant of imatinib who received dasatinib tablets
80 mg/m2 once daily; and (3) patients with CML-CP newly diagnosed who
received either dasatinib tablets 60 mg/m2 once daily or PFOS 72 mg/m2
once daily for$ 12months; patients were then allowed to switch to tablets.
PFOS dose was increased by 20% (to 72 mg/m2) to match the exposure of
the 60 mg/m2 tablet on the basis of bioavailability data in adults. Detailed
inclusion and exclusion criteria are listed in the Data Supplement.
Patients could receive dasatinib until disease progression, un-
acceptable toxicity, or patient/physician preference. Patients who dis-
continued therapy were followed yearly for survival, effects on growth and
development, and effects on bone metabolism up to 5 years after the last
dasatinib dose. The protocol was approved by all institutional review
boards, ethics committees, and national competent authorities at par-
ticipating sites. All patients and/or legal guardians gave written informed
consent and assent where applicable in accordance with the Declaration of
Helsinki and local guidelines.
Evaluations
Primary objectives were to determine major cytogenetic response
(MCyR) for patients with imatinib-resistant/intolerant CML-CP, complete
hematologic response (CHR) for patients with imatinib-resistant/intolerant
CML-AP/BP or Ph+ ALL, and complete cytogenetic response (CCyR) for
Enrolled
(N = 145)
Treated
(n = 130)
Newly diagnosed CML-CP treated
with dasatinib 72 mg/m2 
PFOS once daily*
(n = 33)
Imatinib-resistant/intolerant
CML-AP/BP or Ph+ ALL treated with
dasatinib tablets 80 mg/m2 once daily
(n = 17)
Imatinib-resistant/intolerant CML-CP
treated with dasatinib tablets
60 mg/m2 once daily
(n = 29)
Newly diagnosed CML-CP treated
with dasatinib tablets 60 mg/m2 once daily
(n = 51)
Entered follow-up
Ended follow-up
(n = 9)
(n = 0)
Entered follow-up
Ended follow-up
Death
Patient withdrawal
Lost to follow-up
Other reasonǁ
(n = 14)
(n = 5)
(n = 1)
(n = 1)
(n = 1)
(n = 2)
Entered follow-up
Ended follow-up
Patient withdrawal
(n = 14)
(n = 4)
(n = 4)
Receiving treatment
Discontinued treatment
Progressive disease
Study drug toxicity
Patient withdrawal
Other reason§
(n = 24)
(n = 9)
(n = 1)
(n = 1)
(n = 1)
(n = 6)
Enrollment closed
early as a result of
poor response
Receiving treatment
Discontinued treatment
Progressive disease
Patient withdrawal
Maximum clinical benefit
Noncompliance with study drug
Other reason†
(n = 14)
(n = 15)
(n = 5)
(n = 3)
(n = 2)
(n = 1)
(n = 4)
Receiving treatment
Discontinued treatment
Progressive disease
Patient withdrawal
Maximum clinical benefit
Other reason‡
(n = 37)
(n = 14)
(n = 5)
(n = 2)
(n = 1)
(n = 6)
Excluded
  • Failure to meet study criteria
  • Patient withdrawal
  • Death
  • Other reason
(n = 15)
(n = 11)
(n = 2)
(n = 1)
(n = 1)
Fig 1. CONSORT diagram of study CA180-226. (*)Patients had the option to switch to dasatinib tablets 60 mg/m2 once daily after 1 year of receiving PFOS. (†)Other
includes bone marrow transplant, allogenic bone marrow graft, suboptimal response, and patient lost to follow-up. (‡)Other includes T315I mutation, loss of major
molecular response, investigator decision, loss of complete cytogenetic response (n = 2), and hematopoietic stem cell transplant (n = 2). (§)Other includes hematopoietic
stem cell transplant (n = 2), suboptimal response, second malignancy, and transition to adult hospital (n = 2). (ǁ)Other includes transfer to adult hospital and bone marrow
transplant. CML-AP/BP, chronic myeloid leukemia in accelerated/blast phase; CML-CP, chronicmyeloid leukemia in chronic phase; PFOS, powder for oral suspension; Ph+
ALL, Philadelphia chromosome-positive acute lymphoblastic leukemia.
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patients with newly diagnosed CML-CP at any time. MCyR . 30% for
imatinib-resistant/intolerant CML-CP, CHR . 15% for imatinib-resistant/
intolerant CML-AP/BP or Ph+ ALL, and CCyR. 55% for newly diagnosed
CML-CP were considered of clinical interest and align with historic re-
sponses in pediatric patients with CML-CP.7,8 Secondary objectives
included assessments of safety and evaluation of best cytogenetic and
hematologic response, time to and duration of response, disease-free
survival, progression-free survival (PFS), overall survival (OS), complete
molecular response (CMR), and major molecular response (MMR). The
description of BCR-ABL1mutations at baseline (results of which were not
available before start of study treatment), progression, treatment failure, or
end of treatment, and the exploration of the role of mutations as predictors
of response were also secondary objectives. The database lock for this
analysis was November 2016. Detailed deﬁnitions of efﬁcacy outcomes,
safety assessments, mutational analysis, and statistical methodology can be
found in the Data Supplement.
RESULTS
Patients and Treatments
In total, 145 patients were enrolled between March 2009 and
September 2014. Of these, 130 were treated across three cohorts
(Fig 1): 29 with imatinib-resistant/intolerant CML-CP, 17 with
imatinib-resistant/intolerant CML-AP/BP or Ph+ ALL, and 84
with newly diagnosed CML-CP. Newly diagnosed patients were
either treated with dasatinib tablets (n = 51) or PFOS for
$ 12months (n = 33). Given the observed poor response of patients
with imatinib-resistant/intolerant CML-AP/BP or Ph+ ALL (CHR
was achieved at any time by one of eight patients with CML-BP and
four of nine patients with Ph+ ALL), and that single-agent TKIs are
now considered substandard of care for this pediatric population,
this cohort was closed after 17 patients were enrolled. Discussion of
these data are not included in this report.
Baseline characteristics for the cohorts of CML-CP are in
Table 1. With $ 24 months of follow-up, 14 patients (48%) with
CML-CP resistant to or intolerant of imatinib and 61 patients
(73%) with newly diagnosed CML-CP were still receiving study
treatment. Reasons for exclusion and discontinuation are listed in
Fig 1. Most patients received the protocol-recommended daily dose
of dasatinib (Table 2). Patients who were initiated on PFOS were
allowed to switch to tablets after receiving PFOS for $ 1 year. Of
the 33 patients receiving PFOS, 22 (67%) switched to tablets
because of patient preference. Greater than 38% of patients re-
quired at least one dose interruption, primarily because of dosing
errors and hematologic toxicity (Table 2). Less than 25% of pa-
tients required dose reductions or escalations.
Efficacy
Rates of conﬁrmed CHR (cCHR) achieved at any time on
treatment were 93% (95% CI, 77.2 to 99.2) and 96% (95% CI, 89.9
to 99.3) for patients resistant to or intolerant of imatinib or those
newly diagnosed, respectively. Median time to cCHRwas 0.7months
(95%CI, 0.5 to 1.8) for patients resistant to or intolerant of imatinib
and 1.2 months (95% CI, 0.9 to 1.4) for newly diagnosed patients.
The cumulative rate of MCyR . 30% was reached as early as
3 months for patients with imatinib-resistant/intolerant CML-CP,
and the cumulative rate of CCyR . 55% was reached as early as
6 months for patients with newly diagnosed CML-CP (Fig 2).
Rapid responses were illustrated by a median time to MCyR of
3.1 months (95% CI, 2.8 to 4.1) for those in the imatinib-resistant/
intolerant group and 3.0 months (95% CI, 2.9 to 4.3) for newly
Table 1. Baseline Patient Characteristics
Characteristic
Dasatinib-Treated Patients (n = 113)
Imatinib-Resistant/Intolerant
CML-CP (n = 29)
Newly Diagnosed CML-CP
Tablets (n = 51) PFOS (n = 33) Total (n = 84)
Age, years, median (range)* 13.77 (1.4-20.1) 12.87 (1.9-17.8) 11.70 (1.8-17.5) 12.33 (1.8-17.8)
Age, years, No. (%)*
, 2 1 (3) 1 (2) 1 (3) 2 (2)
$ 2 to , 7 3 (10) 5 (10) 5 (15) 10 (12)
$ 7 to , 12 6 (21) 16 (31) 12 (36) 28 (33)
$ 12 to , 18 17 (59) 29 (57) 15 (45) 44 (52)
Sex, No. (%)
Male 13 (45) 26 (51) 19 (58) 45 (54)
Female 16 (55) 25 (49) 14 (42) 39 (46)
Reason for stopping prior imatinib, No.
Resistance 25 NA NA NA
Intolerance 2 NA NA NA
Undetermined† 2 NA NA NA
Patients with prior therapy, No. (%)
Stem cell transplant 1 (3) 0 0 0
Interferon 4 (14) 1 (2) 0 1 (1)
Hydroxyurea or anagrelide 14 (48) 23 (45) 10 (30) 33 (39)
Chemotherapy‡ 3 (10) 0 0 0
Median time from initial CML diagnosis to ﬁrst dasatinib dose,
months (range)
27.66 (3.0-33.9) 0.69 (0-3.5) 0.46 (0.1-1.4) 0.61 (0-3.5)
Abbreviations: CML-CP, chronic myeloid leukemia in chronic phase; NA, not applicable; PFOS, powder for oral suspension.
*Two patients with imatinib-resistant/intolerant CML-CP were $ 18 years old and were allowed to continue in study despite not meeting enrollment criteria for age.
†Investigator reported the protocol eligibility criteria with regard to imatinib resistance and/or intolerance were not fully met.
‡Limited to cytostatic and antineoplastic agents.
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diagnosed patients, and a median time to CCyR of 3.9 months
(95% CI, 2.8 to 5.6) for patients in the resistant/intolerant CML-
CP group and 5.6 months (95% CI, 5.0 to 6.0) for newly diagnosed
patients (Table 3). Cumulative cytogenetic response rates increased
over time through 24 months, the minimum follow-up for this
analysis (Fig 2). In both cohorts, rates of MCyR increased between
3 and 12 months and were maintained through 24 months. For
patients with CML-CP resistant to or intolerant of imatinib, rates
of CCyR consistently increased. Median durations of cytogenetic
responses were not reached by the time of analysis (Table 3).
Additional assessments were performed to determine the
rates of cytogenetic responses at any time, excluding patients with
MCyR/CCyR or unknown cytogenetic status at baseline. The
results from these assessments were similar to the results cal-
culated using the total number of patients in each cohort (Data
Supplement).
Although they were not focal study end points, the cumulative
rates of MMR and CMRwere also observed to increase over time in
all cohorts (Fig 3). By 12 months, MMR was 41% and CMR was
7% for patients with imatinib-resistant/intolerant CML-CP, and by
24 months, MMR was 55% and CMR was 17% (Figs 3A and 3C).
MMR and CMR were 52% and 8%, respectively, by 12 months and
70% and 21%, respectively, by 24 months for the total newly
diagnosed patient population (Figs 3B and 3D). Cohorts in this
study were not designed to be comparative; however, response rates
appeared to be lower for patients taking the PFOS formulation
versus tablets. Median time to MMR was 8.9 months (95% CI, 8.1
to 11.7) for newly diagnosed patients and was not calculated for the
imatinib-resistant/intolerant cohort.
Median PFS and OS have not been reached in any cohort.
Disease is seven of 29 patients (24%) resistant to or intolerant of
imatinib and seven of 84 newly diagnosed patients (8%) had
progressed at the time of analyses (Data Supplement). Protocol-
deﬁned reasons for progression were loss of MCyR (n = 3 in the
imatinib-resistant/intolerant group; n = 4 newly diagnosed pa-
tients), loss of CHR (n = 2 in each group), and development of
CML-BP (n = 2 in the imatinib-resistant/intolerant group; n = 1 in
the newly diagnosed group). Estimated 48-month PFS was 78%
and 93% for patients with CML-CP resistant to or intolerant of
imatinib and patients with newly diagnosed CML-CP, respectively
(Data Supplement). Similar results were observed for disease-free
survival (Data Supplement). One death was reported: a patient with
CML-CP resistant to or intolerant of imatinib died of gastroin-
testinal bleeding 1 year after stopping dasatinib. This patient had loss
of MCyR before death. There were no deaths reported for patients
with newly diagnosed CML-CP. The estimated 48-month OS rate
was 96% in the imatinib-resistant/intolerant CML-CP cohort.
A post hoc analysis of the proportion of patients with BCR-
ABL1 # 10% versus . 10% at 3 months was performed for the
newly diagnosed cohort. Of the 77 patients with evaluable tran-
script levels at 3 months, 60 (78%) had BCR-ABL1 # 10% and 17
(22%) had BCR-ABL1. 10%. PFS appeared to be higher for newly
diagnosed patients with BCR-ABL1# 10% versus those with BCR-
ABL1 . 10% at 3 months (P , .001; hazard ratio, 0.10; 95% CI,
0.02 to 0.52); estimated 3-year PFS rates were approximately 97%
and 82% for patients with BCR-ABL1 # 10% or . 10% at
3 months, respectively.
BCR-ABL1mutations were assessed at baseline and at the time
of disease progression, treatment failure, or end of treatment. In
the imatinib-resistant/intolerant cohort, six of 27 patients (22%)
evaluated at baseline had a mutation (E255K, F317L, F359V
[n = 2], V379I, Y253H); ﬁve were in cCHR. Of nine patients with
Table 2. Dasatinib Exposure During Study
Characteristic
Dasatinib-Treated Patients (n = 113)
Imatinib-Resistant/Intolerant
CML-CP (n = 29)
Newly Diagnosed CML-CP
Tablets (n = 51) PFOS (n = 33) Total (n = 84)
Average daily dose, mg/m2, median (range) 58.18 (35.1-71.7) 58.54 (37.2-77.9) 64.59 (38.3-98.7) 59.84 (37.2-98.7)
Duration of therapy, months, median (range) 49.91 (1.9-90.2) 52.24 (7.6-75.2) 27.40 (0.1-42.0) 42.30 (0.1-75.2)
Relative dose intensity, No. (%)
50 to , 70 3 (10) 2 (4) 6 (18) 8 (10)
70 to , 90 4 (14) 13 (25) 11 (33) 24 (29)
90 to , 110 19 (66) 33 (65) 15 (45) 48 (57)
$ 110 3 (10) 3 (6) 1 (3) 4 (5)
Patients with $ 1 dose interruption, No. (%) 21 (72) 31 (61) 13 (39) 44 (52)
Dosing error 8 (28) 6 (12) 3 (9) 9 (11)
Hematologic toxicity 5 (17) 13 (25) 6 (18) 19 (23)
Nonhematologic toxicity 6 (21) 9 (18) 4 (12) 13 (15)
Other 2 (7) 3 (6) 0 3 (4)
Duration of ﬁrst interruption, days, median (range) 8 (2-34) 11 (2-35) 11 (4-19) 11 (2-35)
Patients with $ 1 dose reduction, No. (%) 7 (24) 6 (12) 2 (6) 8 (10)
Dosing error 1 (3) 0 0 0
Hematologic toxicity 3 (10) 4 (8) 2 (6) 6 (7)
Nonhematologic toxicity 3 (10) 2 (4) 0 2 (2)
Patients with $ 1 dose escalation, No. (%) 7 (24) 9 (18) 5 (15) 14 (17)
Resistance 4 (14) 7 (14) 3 (9) 10 (12)
Other 3 (10) 2 (4) 1 (3) 3 (4)
No change 0 0 1 (3) 1 (1)
Follow-up, months, median (range) 62.4 (8.0-90.9) 54.3 (16.0-76.6) 32.5 (5.2-42.4) 48.4 (5.2-76.6)
Abbreviations: CML-CP, chronic myeloid leukemia in chronic phase; PFOS, powder for oral suspension.
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assessments at end of treatment, three had a mutation (E255K,
F317L, T315A). The patients with the E255K and F317L mutations
had the samemutation at baseline and end of treatment. No patient
in this cohort had more than one mutation. Mutations in BCR-
ABL1 at T315, F317, and V299 are now considered resistant to
dasatinib,13 which was not fully understood when this trial began.
Of the 78 patients with newly diagnosed CML-CP evaluated at
baseline, one had a P58S mutation that was found in leukemia cells
only. This patient was receiving dasatinib tablets and had cCHR.
There were no mutations detected in the seven patients newly
diagnosed with CML-CP who were evaluated at end of treatment.
Safety
The dasatinib-related adverse events (AEs) of special interest
reported in this study are listed in Table 4. There were no occurrences
A
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Fig 2. Cytogenetic responses over time
for all treated patients. (A) Cumulative rates
of MCyR and (B) cumulative rates of CCyR.
CCyR, complete cytogenetic response;
CML-CP, chronicmyeloid leukemia in chronic
phase; MCyR, major cytogenetic response;
PFOS, powder for oral suspension.
Table 3. Time To and Duration of Response in Patients Treated With Dasatinib
Patient Group
Median Time to Response* Median Duration of Response*
MCyR CCyR MCyR CCyR
Imatinib-resistant/intolerant CML-CP (n = 29) 3.1 (2.8 to 4.1) 3.9 (2.8 to 5.6) NE (54.9 to NE) NE (54.9 to NE)
Newly diagnosed CML-CP
Tablets (n = 51) 3.3 (2.9 to 5.6) 5.7 (3.7 to 6.2) NE (52.7 to NE) NE (49.9 to NE)
PFOS (n = 33) 3.0 (2.8 to 5.0) 5.6 (3.1 to 6.0) NE (NE to NE) NE (NE to NE)
Total (n = 84) 3.0 (2.9 to 4.3) 5.6 (5.0 to 6.0) NE (52.7 to NE) NE (49.9 to NE)
NOTE. Values are months (95% CI).
Abbreviations: CCyR, complete cytogenetic response; CML-CP, chronic myeloid leukemia in chronic phase; MCyR, major cytogenetic response, NE, not estimable,
median not reached; PFOS, powder for oral suspension.
*For patients who had a best response of CCyR or MCyR.
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of pleural effusion, pericardial effusion, pulmonary edema,
pulmonary hypertension, or pulmonary arterial hypertension
related to dasatinib in pediatric patients with CML-CP. In
patients with imatinib-resistant/intolerant CML-CP and newly
diagnosed patients, any-grade myalgia or arthralgia occurred in
17% and 10%, respectively, and fatigue occurred in 14% and
11%, respectively. Dasatinib-related pediatric bone growth and
development AEs were grouped together for reporting pur-
poses. Grade 1/2 events were reported in ﬁve of 113 patients
(4%) with CML-CP. Data on growth and development continue
to be collected and will be reported once mature.
Dasatinib-related serious AEs were reported in ﬁve pa-
tients (17%) with imatinib-resistant/intolerant CML-CP and
eight patients (10%) with newly diagnosed CML-CP (Table 4).
No suspected, unexpected serious adverse reactions were re-
ported. There was one dasatinib-related AE leading to dis-
continuation (grade 3 drug hypersensitivity, which resolved
when the drug was discontinued). Safety assessment of the 17
pediatric patients with CML-AP/BP or Ph+ ALL was consistent
with the known safety proﬁle in adults with advanced Ph+
leukemias.14-16
DISCUSSION
CA180-226 is the largest prospective, registrational trial to date in
pediatric patients diagnosed with CML. With $ 24 months of
follow-up, high response rates and a favorable safety proﬁle for
dasatinib were demonstrated in patient with imatinib-resistant/
intolerant CML-CP and those newly diagnosed with CML-CP.
This study was designed to explore the most clinically relevant
end points for patients with CML at the time the protocol was
developed in 2008: MCyR and CCyR. Overall, the efﬁcacy of
dasatinib in pediatric patients in this trial was similar to or higher
than that historically observed in adults. In a phase III dose-
optimization trial of adults with imatinib-resistant/intolerant
CML-CP, 2-year MCyR was 63%17; in pediatric patients treated
in this study, the MCyR rate by 2 years was 90%. Estimated PFS
rates at 2 years were similar in adults and pediatric patients with
CML-CP resistant to or intolerant of imatinib (80% and 82%,
respectively). In adults with newly diagnosed CML-CP from the
phase III Dasatinib Versus Imatinib Study in Treatment-Naı¨ve
Chronic Myeloid Leukemia Patients (DASISION), the cumulative
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Fig 3. Cumulative rates of molecular responses over time for all treated patients. (A, B) MMR for (A) patients with CML-CP resistant to or intolerant of imatinib and (B)
patients with newly diagnosed CML-CP. (C, D) CMR for (C) patients with CML-CP resistant to or intolerant of imatinib and (D) patients with newly diagnosed CML-CP.
Cohorts were not designed to be comparative. There are numerical differences betweenMMR and CMR in newly diagnosed patients with CML-CP treated with dasatinib
tablets or PFOS, but CIs overlap. CML-CP, chronic myeloid leukemia in chronic phase; CMR, complete molecular response; MMR, major molecular response; PFOS,
powder for oral suspension.
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CCyR rate by 2 years was 86%18; the rate in newly diagnosed
pediatric patients treated in the present study was 94%. Estimated
2-year PFS rates were similar in newly diagnosed adults and pe-
diatric patients (94% and 95%, respectively).
The results described here in patients treated with ﬁrst-line
dasatinib are promising compared with results previously reported
in pediatric patients treated with ﬁrst-line imatinib. The French Na-
tional Phase IV Trial (n = 44), a prospective study of newly diagnosed
pediatric patients with CML-CP treated with imatinib 260 mg/m2
daily, reported CCyR and MMR rates at 12 months of 61% and 31%,
respectively.7 In a study of patients, 18 years of age and treated with
high-dose imatinib (340 mg/m2 daily), 51% achieved CCyR and 30%
achievedMMR at 12months.8 CCyR by 12months was reported to be
72% in newly diagnosed patients, 22 years of age receiving imatinib
340 mg/m2 daily.19 Newly diagnosed pediatric patients treated with
dasatinib in this study hadCCyR andMMR rates by 12months of 92%
and 52%, respectively. MMR is currently considered a more relevant
objective of CML therapy, and ﬁndings in this trial support that deep
and durable molecular remissions are achievable at high levels in
pediatric patients with CML-CP treated with dasatinib.
Achieving early molecular response (EMR) has been associ-
ated with improved long-term outcomes in adults and pediatric
patients with CML treated with TKIs.5,20 For newly diagnosed
pediatric patients treated with dasatinib in this study, 78% achieved
BCR-ABL1 # 10% at 3 months. In the French National Phase IV
Trial, 63% achieved this same milestone with imatinib.21 This
comparison is consistent with results observed in newly diagnosed
adults treated with dasatinib versus imatinib (84% v 64%, re-
spectively).22 Such observed differences between dasatinib and
imatinib may be relevant given the emerging evidence that early,
deep response is of clinical relevance in CML. In newly diagnosed
patient populations treated with dasatinib or imatinib, a signiﬁcant
association between EMR and PFS was observed.21,22 In contrast,
EMR was not correlated with improved outcomes in pediatric
patients treated with high-dose imatinib.23
In adults, more patients receiving dasatinib achieved EMR than
those receiving imatinib; EMR has been shown to predict improved
long-term survival outcomes and deepmolecular responses, currently
a requirement for consideration in TKI discontinuation and dis-
continuation trials.20 Our data suggest a possible role for front-line
Table 4. Dasatinib-Related Adverse Events of Special Interest During This Study
Dasatinib-Related AEs
Dasatinib-Treated Patients (n = 113)
Imatinib-Resistant/
Intolerant CML-CP
(n = 29)
Newly Diagnosed CML-CP
Tablets (n = 51) PFOS (n = 33) Total (n = 84)
Any Grade Grade 3/4 Any Grade Grade 3/4 Any Grade Grade 3/4 Any Grade Grade 3/4
All AEs 26 (90) 11 (38) 41 (80) 20 (39) 28 (85) 12 (36) 69 (82) 32 (38)
AEs of special interest
Nausea and/or vomiting 9 (31) 0 9 (18) 0 8 (24) 0 17 (20) 0
Myalgia or arthralgia 5 (17) 1 (3) 3 (6) 0 5 (15) 0 8 (10) 0
Fatigue 4 (14) 0 3 (6) 0 6 (18) 0 9 (11) 0
Rash 4 (14) 0 11 (22) 0 5 (15) 0 16 (19) 0
Diarrhea 4 (14) 0 11 (22) 0 4 (12) 0 15 (18) 0
Hemorrhage 3 (10) 0 7 (14) 1 (2) 1 (3) 0 8 (10) 1 (1)
Pediatric bone growth and development 3 (10) 0 1 (2) 0 1 (3) 0 2 (2) 0
Shortness of breath 3 (10) 0 1 (2) 0 1 (3) 0 2 (2) 0
Superﬁcial edema 1 (3) 0 3 (6) 0 3 (9) 0 6 (7) 0
Congestive heart failure or cardiac dysfunction 1 (3) 0 2 (4) 0 0 0 2 (2) 0
Generalized edema 0 0 2 (4) 0 0 0 2 (2) 0
Cardiac disorders 0 0 1 (2) 0 0 0 1 (1) 0
Chest pain 0 0 0 0 1 (3) 0 1 (1) 0
SAEs* 5 (17) 5 (17) 6 (12) 5 (10) 2 (6) 1 (3) 8 (10) 6 (7)
Neutropenia 2 (7) 2 (7) — — — — — —
Anemia 1 (3) 1 (3) — — — — 2 (2) 2 (2)
Left ventricular dysfunction 1 (3) 0 — — — — — —
Abnormal hepatic function 1 (3) 1 (3) — — — — — —
Infection 1 (3) 1 (3) — — — — — —
Overdose 1 (3) 0 — — — — 1 (1)† 0
Febrile neutropenia — — — — — — 1 (1) 1 (1)
Hematochezia — — — — — — 1 (1) 1 (1)
Peripheral edema — — — — — — 1 (1) 0
Drug hypersensitivity — — — — — — 1 (1) 1 (1)
Periorbital cellulitis — — — — — — 1 (1) 1 (1)
Decreased white blood cell count — — — — — — 1 (1) 0
Recurrent leukemia — — — — — — 1 (1) 0
Uterine hemorrhage — — — — — — 1 (1) 0
AEs leading to discontinuation 0 0 0 0 1 (3)‡ 1 (3)‡ 1 (1)‡ 1 (1)‡
NOTE. Values are No. (%)
Abbreviations: dash, no data; AE, adverse event; CML-CP, chronic myeloid leukemia in chronic phase; PFOS, powder for oral suspension; SAE, serious adverse event.
*Patients may have had more than one SAE.
†Grade unknown.
‡Drug hypersensitivity.
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dasatinib in achieving earlier and deeper responses in pediatric pa-
tients, although long-term studies would be needed to prove supe-
riority in survival. Permanent discontinuation of TKIs is a key unmet,
and currently unstudied, need in the treatment of pediatric CML.
Efﬁcacy of dasatinib in patients with imatinib-resistant/intolerant
CML-CP in our study is of particular interest because all but two
patients were resistant to imatinib. Long-term data from this trial and
others, as well as randomized trials, are needed to conﬁrm the best
front-line TKI for pediatric patients.
TKI cost should also be considered when choosing a front-line
TKI. With the introduction of generic imatinib in the United
States, imatinib is expected to have a lower initial cost than
dasatinib.24 However, the total cost of dasatinib versus imatinib
over a patient’s life may be less. Our data and data from other
reports suggest that patients receiving dasatinib are more likely to
achieve early and deep responses and may be eligible for TKI
discontinuation.20 Additionally, nonadherence is associated with
increased health care costs,25 and complex treatment regimens
have been shown to decrease adherence.26
Dasatinib has been shown to be better tolerated than imatinib
in adults with CML-CP,22 and there is some evidence, including
results described here, that suggest better tolerability of dasatinib
versus imatinib in children.7 There were no reported pleural ef-
fusion or pulmonary hypertension events in pediatric patients
from this trial or from the phase I study.12 In contrast, dasatinib-
related pleural effusion was reported in 28% of adults with
newly diagnosed and imatinib-resistant/intolerant CML-CP, and
dasatinib-related pulmonary hypertension was reported in 5% of
newly diagnosed adults and 2% adults with imatinib-resistant/
intolerant CML-CP.22,27 It is possible that the pediatric patients in
this study had fewer or no cardiopulmonary comorbidities that
would predispose them to the events seen in adults. It is also
important to investigate potential effects of dasatinib on growth
and development in pediatric patients. Follow-up is ongoing to
characterize the safety of chronic dasatinib use, because pediatric
patients may live for many decades with CML. This will include
assessment of growth and puberty, once the data are more mature.
Long-term follow-up is essential, considering late toxicities of TKIs
have been observed in case reports.2,5,28
A bioequivalence study conducted in adults demonstrated that
the bioavailability of dasatinib PFOS was 19% lower than that of
dasatinib tablets,29 which led to the use of 72 mg/m2 dasatinib
PFOS in this study. Results reported here were similar between
tablets and PFOS; however, this trial was not designed to compare
cohorts. A population pharmacokinetic analysis is ongoing to
evaluate dasatinib PFOS exposure in pediatric patients. Dasatinib
was shown to be safe and well tolerated in pediatric patients at
doses up to 120 mg/m2, with no maximum tolerated dose iden-
tiﬁed in a phase I study.12
This trial was not designed to compare results between co-
horts, dasatinib treatment in children versus adults, or dasatinib
versus imatinib in pediatric patients. Similarities and differences
described here were based on data from separate trials with dif-
ferences in methodology, patient population, and geographic
distribution, which limit interpretation.
Overall, dasatinib treatment produced early, deep, and durable
responses of clinical importance in this largest prospective trial of
pediatric patients with CML-CP to date. Target responses were met
as early as 3 and 6 months for patients with imatinib-resistant/
intolerant CML-CP or newly diagnosed CML-CP, respectively.
Safety of dasatinib was consistent with that reported in adults,
except that no cases of pleural or pericardial effusion or pulmonary
arterial hypertension were observed in pediatric patients. These
results support dasatinib as a safe and effective ﬁrst- or second-line
option for the treatment of pediatric CML-CP.
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